Rigel Pharmaceuticals, Inc. (RIGL) Reaches $4.02 After 9.00% Up Move; Ellomay Capital Limited Ord (NYSEAMERICAN:ELLO) Shorts Decreased By 50%

February 5, 2018 - By Richard Conner

Ellomay Capital Limited Ord (NYSEAMERICAN:ELLO) had a decrease of 50% in short interest. ELLO’s SI was 100 shares in February as released by FINRA. Its down 50% from 200 shares previously. With 300 avg volume, 0 days are for Ellomay Capital Limited Ord (NYSEAMERICAN:ELLO)’s short sellers to cover ELLO’s short positions. It closed at $9.56 lastly. It is down 9.38% since February 5, 2017 and is downtrending. It has underperformed by 26.08% the S&P500.

The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a huge mover today! The stock increased 1.26% or $0.05 during the last trading session, reaching $4.02. About 587,256 shares traded. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 4.56% since February 5, 2017 and is uptrending. It has underperformed by 12.14% the S&P500.The move comes after 8 months positive chart setup for the $588.89M company. It was reported on Feb, 5 by Barchart.com. We have $4.38 PT which if reached, will make NASDAQ:RIGL worth $53.00 million more.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $588.89 million. The companyÂ’s clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

Among 5 analysts covering Rigel Pharmaceuticals (NASDAQ:RIGL), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rigel Pharmaceuticals has $11 highest and $3.25 lowest target. $5.54’s average target is 37.81% above currents $4.02 stock price. Rigel Pharmaceuticals had 18 analyst reports since August 8, 2015 according to SRatingsIntel. On Monday, September 4 the stock rating was maintained by Jefferies with “Buy”. The firm has “Buy” rating by Jefferies given on Monday, May 16. H.C. Wainwright maintained the stock with “Buy” rating in Friday, January 19 report. BMO Capital Markets maintained it with “Buy” rating and $400 target in Wednesday, June 7 report. The rating was initiated by H.C. Wainwright with “Buy” on Wednesday, July 13. The firm has “Buy” rating given on Monday, June 19 by BMO Capital Markets. On Wednesday, August 31 the stock rating was maintained by BMO Capital Markets with “Outperform”. The firm has “Hold” rating by Zacks given on Saturday, August 8. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) earned “Buy” rating by H.C. Wainwright on Monday, November 6. H.C. Wainwright maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rating on Friday, February 2. H.C. Wainwright has “Buy” rating and $7.0 target.

Investors sentiment decreased to 1.39 in Q3 2017. Its down 0.20, from 1.59 in 2017Q2. It fall, as 7 investors sold Rigel Pharmaceuticals, Inc. shares while 24 reduced holdings. 11 funds opened positions while 32 raised stakes. 104.32 million shares or 0.70% less from 105.05 million shares in 2017Q2 were reported. Mackenzie Fincl has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Ascend Cap Ltd Company has invested 0.04% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). First Republic Mgmt reported 52,370 shares. Moreover, Wealthtrust has 0% invested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) for 2,210 shares. Rhenman Prns Asset Management reported 0.76% stake. Tiaa Cref Mgmt Limited Liability Corp holds 0% or 305,136 shares. Barclays Public Ltd Liability Company has 0% invested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) for 168,297 shares. Metropolitan Life Ny holds 0% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) for 161,824 shares. 1.10M are held by Ghost Tree Limited Liability Com. Renaissance Techs Ltd Liability Corp owns 231,736 shares or 0% of their US portfolio. Victory Cap Mngmt accumulated 11,653 shares. Goldman Sachs Gru holds 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) or 187,814 shares. Nj State Employees Deferred Compensation Plan accumulated 290,000 shares or 0.13% of the stock. Bluecrest Capital Mngmt Limited owns 10,549 shares. Schwab Charles Inv Management Inc holds 0% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) for 268,000 shares.

Analysts await Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report earnings on March, 6. They expect $-0.13 EPS, up 18.75% or $0.03 from last year’s $-0.16 per share. After $-0.14 actual EPS reported by Rigel Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -7.14% EPS growth.

Ellomay Capital Ltd. produces and sells renewable and clean energy in Italy and Spain. The company has market cap of $102.06 million. The firm owns 16 photovoltaic plants comprising 12 PV plants in Italy with an aggregate installed capacity of approximately 22.6 MWp and 4 PV plants in Spain with an aggregate installed capacity of approximately 7.9 MWp. It currently has negative earnings. It also operates a bi-fuel power plant with an installed capacity of approximately 850 MWp in the vicinity of Ashkelon, Israel; and constructs pumped storage hydro power plant in the Manara Cliff, Israel, as well as an anaerobic digestion facility in Goor, the Netherlands.